New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

Patients who were prescribed drugs for restless legs syndrome (RLS) have said doctors did not warn them about significant ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Prevalence rates of what GSK calls "deviant" sexual behaviours caused by the drugs are unknown and tend to be under-reported ...

The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...

Two conferences were held in Hanoi and Ho Chi Minh City in early March to discuss shingles in comorbid patients.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV ...

The company will publish its Full-Year 2024 financial results on March 26, 2025. On the reporting date, BioVersys will issue a press release at 7:00 AM CET.